Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPI-387
- Development stage
- Preclinical
- Lead developer
- Defender Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
DPI-387 is a preclinical-stage small molecule drug candidate being developed by Defender Pharmaceuticals for the treatment of Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), and Bipolar Depression. The drug is a scopolamine-related muscarinic acetylcholine receptor antagonist (anticholinergic) designed for intranasal administration. It leverages Defender's intranasal delivery technology and platform molecule, scopolamine, to facilitate rapid delivery to the central nervous system. This approach aims to provide the rapid-acting antidepressant effects associated with scopolamine while optimizing the pharmacokinetic profile through a non-invasive nasal route.
02
Targets
Beyond the preview
Go deeper on DPI-387.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPI-387.